Summary
48.93 1.08(2.26%)10/04/2024
RxSight Inc (RXST)
RxSight Inc (RXST)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.26 | 0.82 | -9.24 | -14.06 | -5.85 | 86.47 | 0.00 | 62,630.77 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 48.93 | |
| Open | 48.65 | |
| High | 49.31 | |
| Low | 47.39 | |
| Volume | 400,250 | |
| Change | 1.08 | |
| Change % | 2.26 | |
| Avg Volume (20 Days) | 343,389 | |
| Volume/Avg Volume (20 Days) Ratio | 1.17 | |
| 52 Week Range | 20.66 - 66.54 | |
| Price vs 52 Week High | -26.47% | |
| Price vs 52 Week Low | 136.83% | |
| Range | 0.58 | |
| Gap Up/Down | -0.42 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,940 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 20.50 | |
| Book Value | 5.5220 | |
| Earnings Per Share | -2.2290 | |
| EPS Estimate Current Quarter | -0.6200 | |
| EPS Estimate Next Quarter | -0.5800 | |
| EPS Estimate Current Year | -2.6200 | |
| EPS Estimate Next Year | -2.3800 | |
| Diluted EPS (TTM) | -2.2290 | |
| Revenues | ||
| Profit Marging | -0.3490 | |
| Operating Marging (TTM) | -2.4327 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 19,081,000 | |
| Revenue per share TTM | 2.4770 | |
| Quarterly Revenue Growth (YOY) | 0.3880 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 1,705,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.1192 | |
| Revenue Enterprise Value | 10.3057 | |
| EBITDA Enterprise Value | 472.6978 | |
| Shares | ||
| Shares Outstanding | 27,353,900 | |
| Shares Float | 13,249,963 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 33.74 | |
| Institutions (%) | 43.35 | |
08/22 16:05 EST - globenewswire.com
RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences
ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September.
RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences
ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September.
08/13 16:50 EST - seekingalpha.com
Investing In The Future Of Cataract Surgery: The RxSight Advantage
RxSight, Inc. is transforming cataract surgery with the Light Adjustable Lens system, offering postoperative customization for superior vision outcomes. The global cataract devices market is rapidly expanding, with RxSight well-positioned to capitalize on the growing demand for premium IOLs. Impressive financial performance in Q2 2024, with significant revenue growth, gross profit margin improvement, and raised full-year revenue guidance.
Investing In The Future Of Cataract Surgery: The RxSight Advantage
RxSight, Inc. is transforming cataract surgery with the Light Adjustable Lens system, offering postoperative customization for superior vision outcomes. The global cataract devices market is rapidly expanding, with RxSight well-positioned to capitalize on the growing demand for premium IOLs. Impressive financial performance in Q2 2024, with significant revenue growth, gross profit margin improvement, and raised full-year revenue guidance.
08/12 10:55 EST - zacks.com
Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?
The mean of analysts' price targets for RxSight (RXST) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?
The mean of analysts' price targets for RxSight (RXST) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
08/05 21:45 EST - seekingalpha.com
RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief Financial Officer Oliver Moravcevic - Vice President, Investor Relations Conference Call Participants Ryan Zimmerman - BTIG Robbie Marcus - J.P. Morgan Steven Lichtman - Oppenheimer & Co. Inc. David Saxon - Needham & Company Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Tom Stephan - Stifel Operator Good day and thank you for standing by.
RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief Financial Officer Oliver Moravcevic - Vice President, Investor Relations Conference Call Participants Ryan Zimmerman - BTIG Robbie Marcus - J.P. Morgan Steven Lichtman - Oppenheimer & Co. Inc. David Saxon - Needham & Company Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Tom Stephan - Stifel Operator Good day and thank you for standing by.
08/05 19:10 EST - zacks.com
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2
RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.40 per share a year ago.
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2
RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.40 per share a year ago.
08/05 16:05 EST - globenewswire.com
RxSight, Inc. Reports Second Quarter 2024 Financial Results
ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2024.
RxSight, Inc. Reports Second Quarter 2024 Financial Results
ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2024.
08/05 11:20 EST - investorplace.com
The 3 Best Med Tech Stocks to Buy Now
According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments.
The 3 Best Med Tech Stocks to Buy Now
According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments.
07/29 10:35 EST - zacks.com
Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround
RxSight (RXST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround
RxSight (RXST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
07/22 16:05 EST - globenewswire.com
RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024
ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024
ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
07/12 10:36 EST - zacks.com
RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for RxSight (RXST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for RxSight (RXST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
06/05 16:05 EST - globenewswire.com
RxSight, Inc. To Participate in the Truist Securities Medtech Conference
ALISO VIEJO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Truist Securities MedTech Conference.
RxSight, Inc. To Participate in the Truist Securities Medtech Conference
ALISO VIEJO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Truist Securities MedTech Conference.
05/28 13:01 EST - zacks.com
What Makes RxSight, Inc. (RXST) a Strong Momentum Stock: Buy Now?
Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes RxSight, Inc. (RXST) a Strong Momentum Stock: Buy Now?
Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.
05/23 09:41 EST - zacks.com
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.
05/13 16:05 EST - globenewswire.com
RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to purchase up to 267,857 additional shares. RxSight's gross proceeds from the offering were $115.0 million, before deducting underwriting discounts and commissions and other offering expenses.
RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to purchase up to 267,857 additional shares. RxSight's gross proceeds from the offering were $115.0 million, before deducting underwriting discounts and commissions and other offering expenses.
05/08 21:15 EST - globenewswire.com
RxSight, Inc. Announces Pricing of Public Offering of Common Stock
ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by RxSight. Before deducting the underwriting discount and estimated offering expenses payable by RxSight, RxSight expects to receive gross proceeds of approximately $100.0 million, assuming no exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about May 13, 2024, subject to satisfaction of customary closing conditions. BofA Securities is acting as lead bookrunning manager of the offering and as representative of the underwriters. J.P. Morgan is also acting as bookrunning manager for the offering. BTIG is acting as co-manager of the offering.
RxSight, Inc. Announces Pricing of Public Offering of Common Stock
ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by RxSight. Before deducting the underwriting discount and estimated offering expenses payable by RxSight, RxSight expects to receive gross proceeds of approximately $100.0 million, assuming no exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about May 13, 2024, subject to satisfaction of customary closing conditions. BofA Securities is acting as lead bookrunning manager of the offering and as representative of the underwriters. J.P. Morgan is also acting as bookrunning manager for the offering. BTIG is acting as co-manager of the offering.
05/06 22:06 EST - seekingalpha.com
RxSight, Inc. (RXST) Q1 2024 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Oliver Moravcevic – Vice President, Investor Relations Ron Kurtz – President and Chief Executive Officer Shelley Thunen – Chief Financial Officer Conference Call Participants Robbie Marcus – JPMorgan Ryan Zimmerman – BTIG Patrick Wood – Morgan Stanley David Saxon – Needham & Company Tom Stephan – Stifel Larry Biegelsen – Wells Fargo Steve Lichtman – Oppenheimer & Co. Operator Good day and thank you for standing by. Welcome to the RxSight First Quarter 2024 Earnings Conference Call.
RxSight, Inc. (RXST) Q1 2024 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Oliver Moravcevic – Vice President, Investor Relations Ron Kurtz – President and Chief Executive Officer Shelley Thunen – Chief Financial Officer Conference Call Participants Robbie Marcus – JPMorgan Ryan Zimmerman – BTIG Patrick Wood – Morgan Stanley David Saxon – Needham & Company Tom Stephan – Stifel Larry Biegelsen – Wells Fargo Steve Lichtman – Oppenheimer & Co. Operator Good day and thank you for standing by. Welcome to the RxSight First Quarter 2024 Earnings Conference Call.
05/06 16:05 EST - globenewswire.com
RxSight, Inc. Reports First Quarter 2024 Financial Results
ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024.
RxSight, Inc. Reports First Quarter 2024 Financial Results
ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024.
04/22 16:05 EST - globenewswire.com
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
04/04 16:05 EST - globenewswire.com
RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
ALISO VIEJO, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
ALISO VIEJO, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
03/27 16:05 EST - globenewswire.com
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference.
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference.